Impact of Cytogenetic Risk on the Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Relapsed/Refractory AML
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
American Journal of Hematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
The Impact of Cytogenetic Risk on the Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Relapsed/Refractory Acute Myeloid Leukemia: On Behalf of the Acute Leukemia Working Party (ALWP) of the EBMT
Am. J. Hematol 2020 Sep 17;[EPub Ahead of Print], M Poiani, M Labopin, G Battipaglia, DW Beelen, J Tischer, J Finke, A Brecht, E Forcade, A Ganser, JR Passweg, H Labussiere-Wallet, I Yakoub-Agha, K Schäfer-Eckart, N Kroeger, B Guffroy, A Ruggeri, J Esteve, A Nagler, M MohtyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.